Next Article in Journal
Improving Molecular Testing and Personalized Medicine in Non-Small-Cell Lung Cancer in Ontario
Previous Article in Journal
Chemonaïveté in Inoperable Malignant Bowel Obstruction
 
 
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Letter

Trastuzumab in Metastatic Breast Cancer after Complete Remission: An Expensive Commitment for an Entire Life?

by
Current Oncology Editorial Office
Multimed Inc., Milton, ON L9T 2R2, Canada
Curr. Oncol. 2017, 24(1), 76-77; https://doi.org/10.3747/co.24.3413
Submission received: 5 November 2016 / Revised: 6 December 2016 / Accepted: 5 January 2017 / Published: 1 February 2017

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

Metastatic breast cancer has consistently been considered an incurable disease. [...]

Share and Cite

MDPI and ACS Style

, C.O.E.O. Trastuzumab in Metastatic Breast Cancer after Complete Remission: An Expensive Commitment for an Entire Life? Curr. Oncol. 2017, 24, 76-77. https://doi.org/10.3747/co.24.3413

AMA Style

COEO. Trastuzumab in Metastatic Breast Cancer after Complete Remission: An Expensive Commitment for an Entire Life? Current Oncology. 2017; 24(1):76-77. https://doi.org/10.3747/co.24.3413

Chicago/Turabian Style

, Current Oncology Editorial Office. 2017. "Trastuzumab in Metastatic Breast Cancer after Complete Remission: An Expensive Commitment for an Entire Life?" Current Oncology 24, no. 1: 76-77. https://doi.org/10.3747/co.24.3413

APA Style

, C. O. E. O. (2017). Trastuzumab in Metastatic Breast Cancer after Complete Remission: An Expensive Commitment for an Entire Life? Current Oncology, 24(1), 76-77. https://doi.org/10.3747/co.24.3413

Article Metrics

Back to TopTop